Negative in Ames, CHO/HGPRT, hepatocyte DNA repair, rat micronucleus and 5-hour CHO chromosome aberration assays
“Gepirone HCl tested negative in 4 genotoxicity assays (Ames, in vivo rat micronucleus, hepatocyte DNA repair, and CHO/HGPRT mammalian gene mutation assays) and in a chromosome aberrations assay conducted in CHO cells with 5 hours treatment.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Carcinogenicity
Rat and mouse carcinogenicity studies: no drug-related tumors up to MTD
“This reviewer agreed with the Sponsor that there were no gepirone-related tumors evident in either rats or mice up to maximum tolerated doses (MTD); concurrence by the Executive-CAC was given on January 8, 2002.”
✓ VerifiedFDA pharmacology/toxicology review, p. 132Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: decreased fetal weight and length with skeletal variations at mid and high doses
“In embryo/fetal development studies, oral administration of gepirone to pregnant rats (75, 150, and 300 mg/kg/day) or pregnant rabbits (50, 100, and 200 mg/kg/day) during the period of organogenesis resulted in decreased embryo/fetal body weights and lengths, with accompanying skeletal variations, at the mid and high doses.”
✓ VerifiedFDA pharmacology/toxicology review, p. 133Source ↗
Safety pharmacology
Reversible decreases in heart rate, blood pressure and contractility without ECG changes; lowered seizure thresholds in rats
“Convulsions were occasionally noted in some general toxicology studies, and gepirone lowered seizure thresholds for strychinine and picrotoxin in rats. Acute cardiac effects were reversible and included decreased heart rate, mean arterial pressure, and contractility, with no apparent alterations in EKG parameters.”
✓ VerifiedFDA pharmacology/toxicology review, p. 38Source ↗
Genotox: Ames
Negative
“It was no mutagenic in the in vitro bacterial reverse mutation assay (Ames test) and was not clastogenic in an in vivo chromosomal aberration test of rat bone marrow cells, but was not adequately tested in an in vitro chromosomal aberration test.”
✓ VerifiedFDA pharmacology/toxicology review, p. 132Source ↗
Genotox: in vitro mammalian
CHO/HGPRT gene mutation and CHO chromosome aberration (5-hour treatment): negative
“Gepirone HCl tested negative in 4 genotoxicity assays (Ames, in vivo rat micronucleus, hepatocyte DNA repair, and CHO/HGPRT mammalian gene mutation assays) and in a chromosome aberrations assay conducted in CHO cells with 5 hours treatment.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Genotox: in vivo
Rat bone marrow micronucleus/chromosomal aberration: negative
“It was no mutagenic in the in vitro bacterial reverse mutation assay (Ames test) and was not clastogenic in an in vivo chromosomal aberration test of rat bone marrow cells, but was not adequately tested in an in vitro chromosomal aberration test.”
✓ VerifiedFDA pharmacology/toxicology review, p. 132Source ↗
Carcinogenicity model
2-year rat and mouse bioassays: no carcinogenic potential
“More importantly, there was no evidence of carcinogenic potential in the completed two-year mouse and rat bioassays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Carcinogenicity timing
2-year mouse and rat bioassays completed before the marketing application; no carcinogenic potential
“More importantly, there was no evidence of carcinogenic potential in the completed two-year mouse and rat bioassays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
hERG / QT
In vivo: reversible decreases in heart rate, MAP and contractility; no EKG changes
“Acute cardiac effects were reversible and included decreased heart rate, mean arterial pressure, and contractility, with no apparent alterations in EKG parameters.”
✓ VerifiedFDA pharmacology/toxicology review, p. 38Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative